drugset / Trial / NCT07266818

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

NCT07266818

Phase 1 Completed 30 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Timeline

Start
2025-12-18
Primary completion
2026-04-09
Completion
2026-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-1167 Unknown Oral

Indications

No indication recorded.